Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals

Authors: Wendy McKinnon, Kimberly C. Banks, Joan Skelly, Wendy Kohlmann, Robin Bennett, Kristen Shannon, Joy Larson-Haidle, Taka Ashakaga, Jeffrey N. Weitzel, Marie Wood

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

Many individuals do not proceed with cancer predisposition testing due to fears of genetic discrimination (GD). We report the results of a survey of 47 unaffected, mutation positive individuals regarding insurance outcomes. Participants recruited from six different Cancer Risk Programs across the country were queried about their experiences with health, life, and disability insurance, as well as employment issues. Eighty-seven percent of participants carried a BRCA mutation and 87% were part of a group insurance plan at the time of testing. Forty-seven percent of participants self-paid for testing. Less than 10% of participants reported that their results were placed in the general medical record, while 43% did not know where their results were placed. Due to concerns about GD, 13% of participants stated they avoided changing jobs. Thirteen percent stated that their at-risk relatives had not undergone testing for the familial mutation due to fears about GD. Adverse events following genetic testing included two denials from private health insurers, one denial for average life insurance coverage and one denial for additional disability insurance. There were no reports of job discrimination. Results suggest fear of GD is prevalent, yet data do not support evidence that GD exists.
Literature
2.
go back to reference Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium (1998) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–271 Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium (1998) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265–271
3.
go back to reference Roa BB, Boyd AA, Volcik K, Sue Richards C (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1(14):185–187. doi:10.1038/ng1096-185 CrossRef Roa BB, Boyd AA, Volcik K, Sue Richards C (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1(14):185–187. doi:10.​1038/​ng1096-185 CrossRef
4.
go back to reference Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689. doi:10.1086/301749 CrossRefPubMed Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689. doi:10.​1086/​301749 CrossRefPubMed
9.
go back to reference Rebbeck TR et al (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87. doi:10.1093/jnci/djn442 CrossRefPubMed Rebbeck TR et al (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87. doi:10.​1093/​jnci/​djn442 CrossRefPubMed
14.
go back to reference American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRef American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRef
15.
go back to reference The NCCN clinical practice guidelines in oncology- genetic/familial high-risk assessment: breast and ovarian. J Nat Compr Canc Netw 2008. V.I. 2008:1–30 The NCCN clinical practice guidelines in oncology- genetic/familial high-risk assessment: breast and ovarian. J Nat Compr Canc Netw 2008. V.I. 2008:1–30
18.
go back to reference Geller G, Bernhardt BA, Doksum T et al (1998) Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women? JCO 16:2868–2876 Geller G, Bernhardt BA, Doksum T et al (1998) Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women? JCO 16:2868–2876
21.
go back to reference Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD (2002) Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epid Biom Prev 11:79–87 Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD (2002) Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epid Biom Prev 11:79–87
22.
go back to reference Geetter JS (2002) The power of the human genome to transform the American insurance system. Am J Law Med 28:1–76PubMed Geetter JS (2002) The power of the human genome to transform the American insurance system. Am J Law Med 28:1–76PubMed
Metadata
Title
Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals
Authors
Wendy McKinnon
Kimberly C. Banks
Joan Skelly
Wendy Kohlmann
Robin Bennett
Kristen Shannon
Joy Larson-Haidle
Taka Ashakaga
Jeffrey N. Weitzel
Marie Wood
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9248-6

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine